Protagenic Therapeutics, Incnew 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
Protagenic Therapeutics reported a significant increase in net loss for Q2 2026, implemented a major restructuring plan, and faces ongoing Nasdaq compliance issues despite a recent reverse merger.
OQB
Protagenic Therapeutics reports a significant net loss in Q1 2026 following a reverse merger, announces a major restructuring, and faces ongoing Nasdaq compliance issues.
OQB
Protagenic Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional financing.
OQB
Protagenic Therapeutics reported a net loss of $640,785 for the third quarter of 2024, alongside updates on their clinical trial for PT00114 and a recent private placement.
OQB
10-Q: Protagenic Therapeutics Reports Increased R&D Spending in Q2 2024, Faces Going Concern Uncertainty
Protagenic Therapeutics' Q2 2024 report reveals increased research and development expenses, leading to a larger operating loss and raising concerns about the company's ability to continue as a going concern.
OQB
Protagenic Therapeutics experienced a significant increase in operating losses during the first quarter of 2024, primarily due to increased research and development expenses.